Trial record 1 of 1 for:    NCT01503515
Previous Study | Return to List | Next Study

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Children's Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01503515
First received: January 1, 2012
Last updated: February 5, 2014
Last verified: February 2014

January 1, 2012
February 5, 2014
March 2013
September 2018   (final data collection date for primary outcome measure)
Development of proven or probable IFI defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [ Time Frame: Up to 42 days following stem cell infusion ] [ Designated as safety issue: No ]
Kaplan-Meier curves will be used to estimate the time to onset of proven/probable IFI for patients randomized to the 2 arms. Log rank test will be used to compare the incidence of IFI between the 2 randomized arms during the at-risk period.
Development of proven or probable invasive fungal infection (IFI) [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01503515 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

This randomized phase II trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.

PRIMARY OBJECTIVES:

I. To determine if caspofungin acetate (caspofungin) is associated with a lower incidence of proven/probable invasive fungal infections (IFI) during the first 42 days following allogeneic hematopoietic cell transplantation (HCT) at high-risk for IFI compared with azole (fluconazole or voriconazole) prophylaxis.

SECONDARY OBJECTIVES:

I. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 100 days following high-risk allogeneic HCT compared with azole (fluconazole or voriconazole) prophylaxis. (Exploratory) II. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 and 100 days following high-risk allogeneic HCT compared with fluconazole prophylaxis. (Exploratory) III. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 and 100 days following high-risk allogeneic HCT compared with voriconazole prophylaxis. (Exploratory) IV. To determine if caspofungin is associated with a superior fungal-free survival (FFS) (time to death or proven/probable IFI) at 42 and 100 days following high-risk allogeneic HCT compared with azole prophylaxis. (Exploratory) V. To describe the effect that caspofungin and azoles have on the incidence and severity of acute graft-versus-host disease (GVHD). (Exploratory) VI. To create a DNA specimen bank in anticipation of the development of biology correlative studies exploring the relationship between IFI and single nucleotide polymorphisms (SNPs) of genes involved in immunity. (Exploratory)

OUTLINE: This is a multicenter study. Patients are stratified by center's choice of azole (fluconazole vs voriconazole), age (>= 12 years vs < 12 years), and type of transplant (umbilical cord blood [UCB] donor vs non-UCB donor with ex vivo T-cell depletion vs non-UCB donor with standard pharmacological graft-versus-host disease prophylaxis). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic hematopoietic stem cell transplantation (HSCT) and continuing until day 42 in the absence of invasive fungal infections or disease progression.

ARM II: Patients receive fluconazole IV over 1-2 hours QD or orally (PO) QD; or voriconazole IV over 1-2 hours QD or PO twice daily (BID) beginning within 24 hours of allogeneic HSCT and continuing until day 42 in the absence of invasive fungal infections or disease progression.

After completion of study treatment, patients are followed up until days 100-114.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
  • Congenital Combined Immunodeficiency
  • Fungal Infection
  • Hematopoietic/Lymphoid Cancer
  • Unspecified Childhood Solid Tumor, Protocol Specific
  • Drug: caspofungin acetate
    Given IV
    Other Names:
    • Cancidas
    • L-743,873
    • MK-0991
  • Drug: fluconazole
    Given IV or PO
    Other Names:
    • Diflucan
    • FCZ
  • Drug: voriconazole
    Given IV or PO
    Other Names:
    • VCZ
    • Vfend
  • Other: laboratory biomarker analysis
    Optional correlative studies
  • Experimental: Arm I (caspofungin acetate)
    Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic hematopoietic stem cell transplant (HSCT) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
    Interventions:
    • Drug: caspofungin acetate
    • Other: laboratory biomarker analysis
  • Active Comparator: Arm II (fluconazole or voriconazole)
    Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT and continuing until day 42 in the absence of invasive fungal infections or disease progression.
    Interventions:
    • Drug: fluconazole
    • Drug: voriconazole
    • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
590
Not Provided
September 2018   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient must be undergoing allogeneic hematopoietic cell transplantation (HCT) for treatment of a malignancy, bone marrow failure syndrome, or congenital immunodeficiency
  • The source for allogeneic stem cells (bone marrow, peripheral blood stem cells [PBSC], or umbilical cord blood) must be an unrelated donor or mismatched (≤ 7/8 at human leukocyte antigen [HLA]-A, B, C, and DR if bone marrow or PBSC; ≤ 5/6 at HLA-A, B, and DR if cord blood) family donor
  • Patients with an elevated galactomannan level (≥ 0.5 Index) within 30 days prior to time of enrollment (if performed) must have a full evaluation for invasive aspergillosis (including a negative chest CT scan) during that time period to be eligible for enrollment
  • Age ≥ 3 months and < 21 years for patients receiving fluconazole as antifungal comparator
  • Age ≥ 2 years and < 21 years for patients receiving voriconazole as the antifungal comparator
  • ECOG scores of 0, 1 or 2 (Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age)
  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL OR serum creatinine based on age/gender as follows:

    • 0.4 mg/dL (1 month to < 6 months of age)
    • 0.5 mg/dL (6 months to < 1 year of age)
    • 0.6 mg/dL (1 to < 2 years of age)
    • 0.8 mg/dL (2 to < 6 years of age)
    • 1.0 mg/dL (6 to < 10 years of age)
    • 1.2 mg/dL (10 to < 13 years of age)
    • 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)
    • 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age (unless the increase in bilirubin is attributable to Gilbert syndrome)
  • SGOT (AST) or SGPT (ALT) < 2.5 times ULN for age
  • Patients with a history of proven or probable invasive mold infection are not eligible
  • Patients with an incompletely treated invasive yeast infection are not eligible
  • Patients with a history of anidulafungin (echinocandin) or azole (fluconazole or voriconazole) hypersensitivity are not eligible
  • Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
  • Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
  • Lactating females are not eligible unless they have agreed not to breastfeed their infants
  • Patients receiving treatment for an invasive fungal infection (IFI) are not eligible
Both
up to 20 Years
No
United States
 
NCT01503515
ACCL1131, NCI-2012-00102, CDR0000721415, COG-ACCL1131, ACCL1131, COG-ACCL1131, ACCL1131, U10CA095861
Yes
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Christopher Dvorak Children's Oncology Group
Children's Oncology Group
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP